NLS Acquisition

PrecisionLife has acquired its long-term Danish technology development partner GenoKey. The acquisition enables PrecisionLife to continue its expansion as an AI-enabled precision medicine company, it states. Financial details of the paper-based transaction were not disclosed. Benefit from GenoKey’s strong relationships with the Danish health system and leading academic clinical research centers PrecisionLife’s platform, which includes […]

Amgen and Five Prime Therapeutics have announced an agreement under which Amgen will acquire Five Prime Therapeutics for USD 38 per share in cash, representing an equity value of approximately USD 1.9 billion. Five Prime’s lead asset, bemarituzumab, is a Phase 3 ready anti-FGFR2b antibody with positive data from a randomized, placebo-controlled Phase 2 study […]

Oasmia Pharmaceutical has signed an agreement with Kazia Therapeutics, an Australian oncology-focused biotechnology company, to acquire exclusive global development rights for Cantrixil, a product candidate in development intended for the treatment of ovarian cancer. The agreement is the first in a series of planned in-licensing deals and acquisitions to expand Oasmia’s oncology portfolio, leveraging its […]

Xbrane Biopharma has entered into a non-binding term-sheet with NewFaDem for a divestment of Primm Pharma. Xbrane’s long term focus is to become a world leading biosimilar developer, and hence Primm Pharma falls outside its strategic scope, the company states in its press release. A total consideration of up to €14 million The non-binding terms […]

Cellink has entered into an agreement with the shareholders of Ginolis to acquire all shares for a purchase price on cash- and debt-free basis of EUR 70 million. Ginolis is a Finnish company focusing on diagnostics automation and advanced robotics solutions for medical and diagnostic industries, according to Cellink’s press release. “With this strategic acquisition […]

Atlas Antibodies has signed an agreement to acquire UK company HistoCyte Laboratories Ltd. HistoCyte Laboratories’ portfolio of cell line materials provides control of immuno-histochemical assays used in the diagnosis of cancers. These materials have tissue-like properties that enhance the quality of tissue-based assays, states Atlas Antibodies in its press-release. “Formed in 2014, HistoCyte Laboratories has […]